Oxyntomodulin

Mechanism

Oxyntomodulin acts as a dual agonist at two Class B G protein-coupled receptors:

1. GLP-1 receptor (GLP1R): Activation suppresses appetite via central pathways (hypothalamus and brainstem), slows gastric emptying, and enhances glucose-dependent insulin secretion. This mirrors the mechanism of selective GLP-1 agonists like semaglutide.

2. Glucagon receptor (GCGR): Activation stimulates hepatic gluconeogenesis and glycogenolysis (raising glucose output) while also increasing energy expenditure and promoting lipolysis. The glucagon component is theorised to counteract the metabolic slowdown often seen with pure GLP-1 agonists.

The dual mechanism is pharmacologically elegant: GLP-1 provides the anorectic signal, while glucagon provides the thermogenic/lipolytic signal. Native OXM has approximately 10-fold lower potency at GLP1R than GLP-1 itself, and modest affinity at GCGR, but its combined effect produces meaningful weight loss in human studies.

Key challenge: DPP-4 rapidly cleaves OXM (N-terminal dipeptide removal), giving it a half-life of approximately 12 minutes in vivo.

Evidence base

Evidence Grade: Moderate

Strengths: Multiple controlled human studies with native OXM; clear mechanistic rationale; validated by the clinical success of engineered analogues (pemvidutide, survodutide) in Phase 2/3 trials.

Limitations: Native OXM studies are small and short-duration (≤4 weeks); no large-scale trials of native OXM exist; practical limitations of short half-life prevent widespread clinical development of the native peptide.

Key studies:

• Wynne K et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes. 2005;54(8):2390–2395.
• Dakin CL et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab. 2004;89(9):4604–4607.
• Cohen MA et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab. 2003;88(10):4696–4701.
• Pocai A. Action and therapeutic potential of oxyntomodulin. Mol Metab. 2014;3(3):241–251.

Protocols

Native oxyntomodulin has been studied in humans primarily via continuous subcutaneous infusion at approximately 400 pmol/kg/min for up to 4 weeks. Its very short half-life (~12 minutes) makes bolus dosing impractical. Research-grade OXM is typically used as a reference compound in receptor binding and signalling assays rather than in in vivo dosing studies. Most contemporary metabolic research into the OXM pharmacophore uses long-acting engineered analogues. These protocols are described for research documentation only.

UK legal status

Oxyntomodulin is not a licensed medicine in the UK, not MHRA-registered, and not a controlled substance. It may be sold as a research reagent. Native OXM is rarely available from research peptide vendors due to its impractical pharmacokinetics; researchers typically use long-acting analogues for in vivo studies.

Vendor notes

Native oxyntomodulin has limited commercial availability from research peptide suppliers due to its very short half-life and DPP-4 sensitivity. Researchers interested in the OXM dual-agonist pharmacology are generally directed to long-acting analogues (pemvidutide, survodutide, mazdutide), which are available from select suppliers. Researchers should verify COAs and purity for any OXM sourced for in vitro assay use.